相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study
George Grunberger et al.
DIABETES THERAPY (2018)
Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study
George Grunberger et al.
DIABETES THERAPY (2018)
Analysis of Fractures in Patients With Type 2 Diabetes Treated With Empagliflozin in Pooled Data From Placebo-Controlled Trials and a Head-to-Head Study Versus Glimepiride
Sven Kohler et al.
DIABETES CARE (2018)
Adverse effects of SGLT2 inhibitors on bone health
Jenny E. Blau et al.
NATURE REVIEWS NEPHROLOGY (2018)
Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study
Sam Miller et al.
DIABETES THERAPY (2018)
Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study
Sam Miller et al.
DIABETES THERAPY (2018)
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
Christoph Wanner et al.
CIRCULATION (2018)
Diagnosis and management of bone fragility in diabetes: an emerging challenge
S. L. Ferrari et al.
OSTEOPOROSIS INTERNATIONAL (2018)
Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study
Samuel Dagogo-Jack et al.
DIABETES OBESITY & METABOLISM (2018)
Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET)
Julio Rosenstock et al.
DIABETES OBESITY & METABOLISM (2018)
Mechanisms of diabetes mellitus-induced bone fragility
Nicola Napoli et al.
NATURE REVIEWS ENDOCRINOLOGY (2017)
Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
Ralph A. DeFronzo et al.
NATURE REVIEWS NEPHROLOGY (2017)
Canagliflozin in Conjunction With Sulfonylurea Maintains Glycemic Control and Weight Loss Over 52 Weeks: A Randomized, Controlled Trial in Patients With Type 2 Diabetes Mellitus
Jean-Francois Yale et al.
CLINICAL THERAPEUTICS (2017)
Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis
Darin Ruanpeng et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2017)
Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial
Takashi Kadowaki et al.
DIABETES OBESITY & METABOLISM (2017)
Should Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes?
George Grunberger
CURRENT DIABETES REPORTS (2017)
Pathophysiology of Bone Fragility in Patients with Diabetes
Andrea Palermo et al.
CALCIFIED TISSUE INTERNATIONAL (2017)
Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease - Results From EMPA-REG OUTCOME®
Kohei Kaku et al.
CIRCULATION JOURNAL (2017)
Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placebo-controlled, double-blind, multicenter trial
Chieh-Hsiang Lu et al.
JOURNAL OF DIABETES INVESTIGATION (2016)
Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes
Sven Kohler et al.
CLINICAL THERAPEUTICS (2016)
Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin
H. W. Rodbard et al.
DIABETES OBESITY & METABOLISM (2016)
Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials
H. L. Tang et al.
DIABETES OBESITY & METABOLISM (2016)
Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin
John P. Bilezikian et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus
Nelson B. Watts et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16-week double-blind treatment period
Eiichi Araki et al.
JOURNAL OF DIABETES INVESTIGATION (2016)
Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial
Wenying Yang et al.
JOURNAL OF DIABETES (2016)
Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes
Chantal Mathieu et al.
DIABETES CARE (2015)
Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes
B. Bode et al.
DIABETES OBESITY & METABOLISM (2015)
Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial
J. Rosenstock et al.
DIABETES OBESITY & METABOLISM (2015)
Trabecular Bone Score as an Indicator for Skeletal Deterioration in Diabetes
Jung Hee Kim et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review
A. Palermo et al.
OSTEOPOROSIS INTERNATIONAL (2015)
Possible adverse effects of SGLT2 inhibitors on bone
Simeon I. Taylor et al.
LANCET DIABETES & ENDOCRINOLOGY (2015)
Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes
Bruce Neal et al.
DIABETES CARE (2015)
Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial
Hans-Ulrich Haering et al.
DIABETES CARE (2014)
Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes
Julio Rosenstock et al.
DIABETES CARE (2014)
Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial
C. S. Kovacs et al.
DIABETES OBESITY & METABOLISM (2014)
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin
J. Bolinder et al.
DIABETES OBESITY & METABOLISM (2014)
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease
J. -F. Yale et al.
DIABETES OBESITY & METABOLISM (2014)
Efficacy and safety of dapaglflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise
K. Kaku et al.
DIABETES OBESITY & METABOLISM (2014)
Dapagliflozin Added to Usual Care in Individuals with Type 2 Diabetes Mellitus with Preexisting Cardiovascular Disease: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study with a 28-Week Extension
Lawrence A. Leiter et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2014)
Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
Donald E. Kohan et al.
KIDNEY INTERNATIONAL (2014)
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
Anthony H. Barnett et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
Clifford J. Bailey et al.
BMC MEDICINE (2013)
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
Michael Roden et al.
LANCET DIABETES & ENDOCRINOLOGY (2013)
Effects of SGLT2 inhibitors on cardiovascular outcomes
Celine Foote et al.
DIABETES & VASCULAR DISEASE RESEARCH (2012)
Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy
Julio Rosenstock et al.
DIABETES CARE (2012)
Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin
O. Ljunggren et al.
DIABETES OBESITY & METABOLISM (2012)
分享论文
